Market Development Manager
Exagen
Market Development Manager
Exagen
Autoimmune rheumatology diagnostic testing platform
Exagen is a patient-focused and discovery-driven life sciences company dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases, including lupus and rheumatoid arthritis. By leveraging our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology, we help get to the real cause of a patient’s symptoms and guide their journey to improved health.
About the Opportunity:
Our commercial team is a group of passionate, hard-working, fun people aligned to our vision of delivering value to our customers resulting in better patient care.
We are seeking dynamic, award-winning, high-performing sales professionals to join our commercial sales organization. As an MDM, you are the face of Exagen to our customers. You ensure that customers understand Exagen’s Autoimmune Diagnostic/Therapeutic (DxRx) Vision and value by professionally promoting our products and services to Health Care Providers (HCPs), staff, and other decision-makers.
Location Note: This position supports our West Palm Beach territory and candidates must live within commuting distance.
The role’s main objectives:
Benefits: We offer a competitive benefits package designed to support the health, financial well-being, and work-life balance of our employees, including medical, dental, and vision insurance; Health Care and Dependent Care Flexible Spending Accounts; a 401(k) retirement savings program; 4 weeks paid time off (PTO); paid company holidays; employer-paid life insurance; optional life insurance; and employer-paid short-term and long-term disability insurance.
Exagen provides diagnostic tests for autoimmune rheumatic diseases using the AVISE testing platform. It analyzes Cell-Bound Complement Activation Products (CB-CAPs) to assess complement activation and aid differential diagnosis, with AVISE CTD supporting differentiation of connective tissue diseases such as lupus, rheumatoid arthritis, and Sjögren’s syndrome. The tests offer information for prognosis, disease activity monitoring, and therapeutic drug level assessment, aiming for higher sensitivity and specificity compared with traditional markers. Revenue comes from selling AVISE tests to healthcare providers, with goals to become the standard of care in rheumatology following milestones like the one-millionth AVISE CTD test and IPO-backed expansion.
Explore more opportunities at Exagen